Acute Porphyria Drug Database

Monograph

R03CC12 - Bambuterol
Propably not porphyrinogenic
PNP

Rationale
Only limited hepatic load. Probably non-CYP metabolism. About 10 % of the absorbed dose gives rise to terbutaline ( i.e. 0.2-0.5 mg) "Rather low dose in large part not metabolised. No data pointing to CYP-interaction. One reference: authorised."
Chemical description
Long-acting adrenergic bronchodilator for systemic use (tabl. 10 - 20 mg, mixture 1mg/mL). used in bronchial asthma where glucocorticoide effect is insufficient. Prodrug to the beta-receptor agonist terbutaline. Only about 20 % of the dose is absorbed. About 1/3 is metabolized in the intestinal wall to intermediary metabolites. About 10% gives rise to terbutaline.
Similar drugs
Explore alternative drugs in similar therapeutic classes R03C / R03CC or go back.
Tradenames
This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.


Bambec Bambec
 
© NAPOS 2025
An unhandled error has occurred. Reload 🗙